Optimization of cisplatin for the treatment of hormone-dependent tumoral diseases: Part 2: Use of non-steroidal ligands

Platinum complexes with carrier ligands were synthesized to overcome intrinsic and acquired resistance of the tumors during the therapy. For the treatment of breast and prostate cancer steroidal and non-steroidal ligands are available. This article is a critical review of the attempts made during the last three decades to design platinum complexes with a selective mode of action against hormone-dependent tumors. In part 1 of this paper the use of steroidal carrier ligands is described while in part 2 the view is focussed on derivatives of non-steroidal drugs suitable to coordinate to platinum. Especially the [1,2-diarylethylenediamine]platinum(II) complexes are interesting analogous of cisplatin.